Get the Stockscreener App
27.65
0.61%
-0.17
After Hours:
27.40
-0.25
-0.90%
Beam Therapeutics Inc stock is traded at $27.65, with a volume of 1.49M.
It is down -0.61% in the last 24 hours and up +4.89% over the past month.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
See More
Previous Close:
$27.82
Open:
$28.08
24h Volume:
1.49M
Relative Volume:
1.30
Market Cap:
$2.29B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-15.28
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+1.36%
1M Performance:
+4.89%
6M Performance:
+8.35%
1Y Performance:
-0.82%
1-Day Range:
$27.52
$28.95
1-Week Range:
$24.32
$28.95
52-Week Range:
$20.84
$49.50
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.65 | 2.29B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics (NASDAQ:BEAM) Shares Up 8%Still a Buy? - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) CEO Sells $802,500.00 in Stock - MarketBeat
What is HC Wainwright's Estimate for BEAM FY2026 Earnings? - MarketBeat
(BEAM) Long Term Investment Analysis - Stock Traders Daily
Brokers Set Expectations for BEAM Q1 Earnings - MarketBeat
H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com India
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com Australia
HC Wainwright Reaffirms "Buy" Rating for Beam Therapeutics (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Shares Gap UpWhat's Next? - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for BEAM Earnings - MarketBeat
Top 5 CRISPR Companies To Invest In (February 2025) - Securities.io
(BEAM)Analyzing Beam Therapeutics's Short Interest - Benzinga
Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares - Simply Wall St
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week - Yahoo Finance
Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Cantor Fitzgerald Upgrades Beam Therapeutics (BEAM) - MSN
Demystifying Beam Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Beam Therapeutics (NASDAQ:BEAM) Raised to "Overweight" at Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Upgrades Beam Therapeutics to Overweight From Neutral -January 29, 2025 at 07:29 am EST - Marketscreener.com
Wall Street Analysts Think Beam Therapeutics (BEAM) Could Surge 84.45%: Read This Before Placing a Bet - Yahoo Finance
Is it a Good Idea to Invest in Beam Therapeutics Stock Now? - MSN
Leerink Partnrs Issues Optimistic Forecast for BEAM Earnings - Defense World
(BEAM) Investment Report - Stock Traders Daily
FY2024 Earnings Estimate for BEAM Issued By Leerink Partnrs - MarketBeat
Cantor Fitzgerald Predicts BEAM FY2025 Earnings - Defense World
Research Analysts Issue Forecasts for BEAM FY2025 Earnings - MarketBeat
Beam Therapeutics to present updated BEAM-101 trial data - Investing.com India
Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR - The Manila Times
Beam Therapeutics to present updated BEAM-101 trial data By Investing.com - Investing.com UK
Beam Therapeutics to Encore Data from BEACON Phase 1/2 - GlobeNewswire
Beam Therapeutics' BEAM-101 Shows Strong Results in Sickle Cell Disease Trial Data - StockTitan
Has Alzamend Neuro (ALZN) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Beam Therapeutics Shares Cross Above 200 DMA - Nasdaq
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts - Seeking Alpha
50,285 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Bought by Avanza Fonder AB - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones - MSN
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones By Investing.com - Investing.com South Africa
Beam Therapeutics (NASDAQ:BEAM) Shares Down 8%Should You Sell? - MarketBeat
Beam Therapeutics’ (BEAM) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Beam Therapeutics (NASDAQ:BEAM) Given Outperform Rating at Wedbush - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Trading Down 8%Time to Sell? - MarketBeat
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? - MSN
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates By Investing.com - Investing.com South Africa
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates - Investing.com India
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):